Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Drug development company Lab International has initiated enrollment in a phase I trial for its new asthma product Lab CGRP, or calcitonin gene related peptide.
Subscribe to our email newsletter
The placebo-controlled dose escalation study is being conducted in Europe to investigate the safety and tolerability of inhaled CGRP in 10 healthy volunteers.
The company expects to complete the trial in time to file an investigational new drug (IND) application or equivalent so that it can initiate a phase II study for testing bronchodilatory properties of the product before the end of the year.
“Based on preclinical study results, Lab CGRP has been shown to be effective for prevention and treatment of early and late stage bronchial response to allergens and did not reveal any safety concerns,” said Halvor Jaeger, CEO of Lab. “It has also demonstrated, unlike current asthma drugs, unique combined broncho-dilatory, anti-inflammatory and broncho-protective properties.”
It has been estimated that the asthma / COPD (chronic obstructive pulmonary diseases) total market could reach more than $17bn by the year 2009 with more than 100 million sufferers worldwide.